IPO Report: Kenvue stock cheered in Wall Street debut, as Tylenol and Band-Aid brand parent is valued at $48 billion

by | May 4, 2023 | Stock Market

The newly minted shares of Kenvue Inc. were cheered in their Wall Street debut Thursday, as the Johnson & Johnson spinoff saw its stock open 16.0% above where the initial public offering was priced. Kenvue
the parent of a number of household consumer brands, including Tylenol, Band-Aid, Listerine and Benadryl, said late Wednesday that it sold 172.8 million shares in the IPO, up from previous expectations of 151.2 million shares. The company raised $3.80 billion, as the IPO priced at $22 a share, which was at the higher end of the expected pricing range of between $20 and $23 a share.

With 1.87 billion shares outstanding after the IPO, the pricing valued the company at $41.08 billion. That made it the biggest IPO since late 2021. The stock’s first trade on the New York Stock Exchange was at $25.53 at 12:47 p.m. Eastern, for 15.7 million shares. At the opening price, the company’s market capitalization was at $47.7 billion. It has added to gains since the open, as it was 19.5% above its IPO price in afternoon trading to boost the company’s market cap to $49.1 billion. “With over $2 billion in cash flow and a healthy 3.7% dividend, this is exactly the type of deal that works in a tough environment,” said Bill Smith, co-founder of Renaissance Capital. Kenvue has reported net income of $2.09 billion on sales of $14.95 billion for the fiscal year ended Jan. 1, 2023, compared with net income of $2.03 billion on sales of $15.05 billion …

Article Attribution | Read More at Article Source

Share This